“A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide” has been added to your cart. View cart
Armed with this information, the healthcare professional may be better able to understand and evaluate the clinical evidence for the use of medications for the treatment of bipolar disorder and schizophrenia.
Grants an Individual with Unlimited Access To Over 10,000 Journal Article Pages and Supplements with a Digital Subscription to Psychopharmacology Bulletin